控糖不再伤“心”丨糖尿病新药Farxiga可降低心衰风险

2018-11-20 佚名 汉鼎好医友

糖尿病最怕的地方不在于它本身,而在于它所导致的并发症。特别是对血糖管理不好的人来说,血糖长期的增高会使大血管、微血管受损,并且危害到心、脑、肾、周围神经、眼睛、足等部位,后果不堪设想。有数据显示,糖友发病后的10年左右,30%~40%的人会发生至少一种并发症,而且并发症一旦产生,用药物来治疗很难逆转。在糖尿病并发症中,由心脑血管病变导致的死亡占糖尿病死亡一半以上,10%左右是肾病变所致,并且糖尿病

糖尿病最怕的地方不在于它本身,而在于它所导致的并发症。特别是对血糖管理不好的人来说,血糖长期的增高会使大血管、微血管受损,并且危害到心、脑、肾、周围神经、眼睛、足等部位,后果不堪设想。

有数据显示,糖友发病后的10年左右,30%~40%的人会发生至少一种并发症,而且并发症一旦产生,用药物来治疗很难逆转。在糖尿病并发症中,由心脑血管病变导致的死亡占糖尿病死亡一半以上,10%左右是肾病变所致,并且糖尿病截肢患者是非糖尿病的10~20倍。

此前,已有研究称:抗糖尿病药物可保护大脑免受阿尔茨海默病的侵害。而最近一项新的研究表明,治疗糖尿病的药物Farxiga可能会帮助患者抵御另一个 “杀手”--心力衰竭。

这项由Astra-Zeneca制药公司资助的研究包括超过17000名年龄在40岁以上的2型糖尿病患者。其中近7000人患有心脏病,超过10000人有多种心脏病的危险因素。患者被随机分配到每天服用安慰剂或10毫克Farxiga的两组。

Farxiga是一种钠-葡萄糖协调转运蛋白2(SGLT2)抑制剂的药物,美国食品药品管理局(FDA)于2014年1月8日批准其用于2型糖尿病的治疗。

研究小组发现,虽然服用这种药物并没有降低心脏病、中风和心血管相关死亡的风险。然而,服用该药患者的血糖水平确实出现了健康的下降;同时,他们因心力衰竭而住院的风险降低了27%;而且,他们患肾衰竭和死于肾衰竭的风险也有所降低。

研究作者、波士顿布莱根和妇女医院心血管医学专家斯蒂芬·维沃特(Stephen Wiviott)博士说:“在选择治疗方法时,这样的试验结果可以帮助我们做出明智的决定,知道哪些治疗方法不仅对降低血糖安全有效,而且可以降低心脏和肾脏并发症的风险。”

他还指出,最近对Farxiga这类药物的另外两项研究也表明,它们在广大糖尿病患者中有力且持续地改善了患者心脏和肾脏的预后。

过去人们担心一些糖尿病药物可能会损害心脏,但这项新研究表明,现在有新的药物对心血管有益,这对糖尿病患者来说是个好消息。

纽约曼哈塞特北岸大学医院心内科主任Cindy Grines博士指出:“积液是心力衰竭的一个标志。而Farxiga可通过增加尿液中葡萄糖的排泄,减低心力衰竭的风险。美中不足的是这种药物并没有降低心脏病和中风的发病率。然而,普通的糖尿病药物二甲双胍已经被证明可以降低这些心脏事件的风险。因此,可以选择在充血性心力衰竭患者中添加二甲双胍。”

同时,Grines提醒有心脏问题的患者应该特别避免服用磺酰脲类糖尿病药物。因为多项研究表明,磺酰脲类药物如:格列吡嗪、格列脲和格列咪脲等会增加患者心血管死亡率、心脏病和充血性心力衰竭的发作。

纽约市史坦顿岛大学医院的心脏病专家Marcin Kowalski博士表示:“Farxiga用以减少心力衰竭将是一个很受欢迎的补充,同样令人振奋的是,这组药物并没有增加负面的心血管结果。” 另一位心脏病专家也认为,Farxiga等新药正在改善2型糖尿病患者的治疗。

这项研究结果发表在最新一期《新英格兰医学杂志》上。

参考资料

[1] Diabetes Drug Might Also Ease Heart Failure Risks.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1219878, encodeId=661512198e890, content=2022年回头来看 ,sglt2i已经成为了心衰的金四角,哈哈哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220709/a510c1d082a042b5b7d85344c7f8539a/000346081d9f44ca9473cfda715d2eea.jpg, createdBy=5eec5483989, createdName=十八线开外美少女, createdTime=Mon May 16 01:35:56 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257533, encodeId=7463125e53354, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7247, encryptionId=b6b5e2474b, topicName=Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Thu Nov 22 10:54:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389459, encodeId=d78e138945918, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Nov 22 10:54:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503916, encodeId=6833150391692, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Thu Nov 22 10:54:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042051, encodeId=98ab1042051a5, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Nov 20 22:54:00 CST 2018, time=2018-11-20, status=1, ipAttribution=)]
    2022-05-16 十八线开外美少女

    2022年回头来看 ,sglt2i已经成为了心衰的金四角,哈哈哈哈

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1219878, encodeId=661512198e890, content=2022年回头来看 ,sglt2i已经成为了心衰的金四角,哈哈哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220709/a510c1d082a042b5b7d85344c7f8539a/000346081d9f44ca9473cfda715d2eea.jpg, createdBy=5eec5483989, createdName=十八线开外美少女, createdTime=Mon May 16 01:35:56 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257533, encodeId=7463125e53354, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7247, encryptionId=b6b5e2474b, topicName=Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Thu Nov 22 10:54:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389459, encodeId=d78e138945918, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Nov 22 10:54:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503916, encodeId=6833150391692, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Thu Nov 22 10:54:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042051, encodeId=98ab1042051a5, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Nov 20 22:54:00 CST 2018, time=2018-11-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1219878, encodeId=661512198e890, content=2022年回头来看 ,sglt2i已经成为了心衰的金四角,哈哈哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220709/a510c1d082a042b5b7d85344c7f8539a/000346081d9f44ca9473cfda715d2eea.jpg, createdBy=5eec5483989, createdName=十八线开外美少女, createdTime=Mon May 16 01:35:56 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257533, encodeId=7463125e53354, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7247, encryptionId=b6b5e2474b, topicName=Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Thu Nov 22 10:54:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389459, encodeId=d78e138945918, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Nov 22 10:54:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503916, encodeId=6833150391692, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Thu Nov 22 10:54:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042051, encodeId=98ab1042051a5, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Nov 20 22:54:00 CST 2018, time=2018-11-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1219878, encodeId=661512198e890, content=2022年回头来看 ,sglt2i已经成为了心衰的金四角,哈哈哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220709/a510c1d082a042b5b7d85344c7f8539a/000346081d9f44ca9473cfda715d2eea.jpg, createdBy=5eec5483989, createdName=十八线开外美少女, createdTime=Mon May 16 01:35:56 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257533, encodeId=7463125e53354, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7247, encryptionId=b6b5e2474b, topicName=Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Thu Nov 22 10:54:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389459, encodeId=d78e138945918, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Nov 22 10:54:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503916, encodeId=6833150391692, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Thu Nov 22 10:54:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042051, encodeId=98ab1042051a5, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Nov 20 22:54:00 CST 2018, time=2018-11-20, status=1, ipAttribution=)]
    2018-11-22 yibei
  5. [GetPortalCommentsPageByObjectIdResponse(id=1219878, encodeId=661512198e890, content=2022年回头来看 ,sglt2i已经成为了心衰的金四角,哈哈哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220709/a510c1d082a042b5b7d85344c7f8539a/000346081d9f44ca9473cfda715d2eea.jpg, createdBy=5eec5483989, createdName=十八线开外美少女, createdTime=Mon May 16 01:35:56 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257533, encodeId=7463125e53354, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7247, encryptionId=b6b5e2474b, topicName=Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Thu Nov 22 10:54:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389459, encodeId=d78e138945918, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Nov 22 10:54:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503916, encodeId=6833150391692, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Thu Nov 22 10:54:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042051, encodeId=98ab1042051a5, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Nov 20 22:54:00 CST 2018, time=2018-11-20, status=1, ipAttribution=)]
    2018-11-20 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

糖尿病患者血脂异常,如何处理?

今天跟大家一起来探讨一下如何规范诊治血脂异常的糖尿病患者,请看下面这个病例